Market Cap 20.84M
Revenue (ttm) 320,000.00
Net Income (ttm) -11.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,509.37%
Debt to Equity Ratio 0.21
Volume 118,000
Avg Vol 207,488
Day's Range N/A - N/A
Shares Out 15.91M
Stochastic %K 25%
Beta 0.53
Analysts Sell
Price Target $10.25

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 401 426 4664
Address:
123 E. Tarpon Ave., Tarpon Springs, United States
bentley99
bentley99 Jul. 2 at 7:12 PM
$AKBA AI picked this $ALLR and $IKT as potential moonshots. $UNCY is recovering while waiting on $OMER As an alternate to $OMER AI picked$TARS
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 2 at 7:04 PM
$GERN a nice long hem/onc hold like $CCCC or $ALLR or $IMRX
0 · Reply
Wody
Wody Jul. 2 at 3:53 PM
$ALLR buyout at $1.30?
1 · Reply
selftaught
selftaught Jul. 2 at 3:16 PM
$ALLR You are now on my list.
0 · Reply
ZacksResearch
ZacksResearch Jul. 2 at 12:26 PM
$ALLR strengthens its long-term ovarian cancer strategy with new U.S. patent protection through 2042 🔒 Allarity secured a key U.S. patent covering its stenoparib DRP companion diagnostic, reinforcing its precision medicine approach and extending intellectual property protection for its lead ovarian cancer program. The company continues advancing stenoparib in Phase 2 studies as it works toward potential FDA approval. 👉 Price target breakdown here 👇 https://www.zacks.com/stock/research/ALLR/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-38611&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_38611
1 · Reply
focafoca99
focafoca99 Jul. 1 at 12:39 PM
$ALLR awarded a key U.S. patent for its DRP companion diagnostic, expanding its biotech IP portfolio.
1 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 30 at 3:05 PM
$ALLR The Baseline Law: You can have the most miraculous clinical data in the world, but if your patent protection is weak, your corporate value is essentially zero. A biotech company's patent portfolio is completely equal in importance to its clinical trial data. They are the two pillars of a single equation: Data proves the drug works; Patents prove you can make money from it. Updated report 👇
1 · Reply
Wody
Wody Jun. 30 at 2:41 PM
$ALLR they always seem to send news in bunches…hopefully tomorrow morning!
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 30 at 1:11 PM
$ALLR 💎 🤩 👊
0 · Reply
Wody
Wody Jun. 30 at 12:47 PM
$ALLR $5 here we come…
0 · Reply
Latest News on ALLR
Allarity receives notice of allowance from USPTO

2026-04-27T13:21:02.000Z - 2 months ago

Allarity receives notice of allowance from USPTO


Allarity closes $20M financing for stenoparib advancement

2026-03-06T13:19:41.000Z - 4 months ago

Allarity closes $20M financing for stenoparib advancement


Allarity doses first patients in Phase 2 trial of SCLC

2026-02-18T13:25:56.000Z - 4 months ago

Allarity doses first patients in Phase 2 trial of SCLC


Allarity CEO says 2026 represents an ‘inflection point’

2025-12-31T13:05:34.000Z - 6 months ago

Allarity CEO says 2026 represents an ‘inflection point’


Allarity files $50M mixed securities shelf

2025-12-03T14:15:27.000Z - 7 months ago

Allarity files $50M mixed securities shelf


Allarity reports Q3 EPS (19c) vs ($7.71) last year

2025-11-14T14:06:08.000Z - 8 months ago

Allarity reports Q3 EPS (19c) vs ($7.71) last year


Allarity files to sell 1.56M shares of common stock for holders

2025-09-25T21:25:29.000Z - 10 months ago

Allarity files to sell 1.56M shares of common stock for holders


Allarity presents new Phase 2 clinical data for Stenoparib

2025-09-22T12:20:54.000Z - 10 months ago

Allarity presents new Phase 2 clinical data for Stenoparib


Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

2025-08-27T01:00:00.000Z - 11 months ago

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?


Allarity initiated with a Buy at Ascendiant

2025-07-28T09:50:42.000Z - 1 year ago

Allarity initiated with a Buy at Ascendiant


Allarity appoints Jeff Ervin as CFO

2025-07-07T12:26:02.000Z - 1 year ago

Allarity appoints Jeff Ervin as CFO


Allarity Therapeutics Announces Changes to Board of Directors

Jun 11, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Announces Changes to Board of Directors


Allarity announces research collaboration with IBRI

2025-06-04T12:05:09.000Z - 1 year ago

Allarity announces research collaboration with IBRI


bentley99
bentley99 Jul. 2 at 7:12 PM
$AKBA AI picked this $ALLR and $IKT as potential moonshots. $UNCY is recovering while waiting on $OMER As an alternate to $OMER AI picked$TARS
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 2 at 7:04 PM
$GERN a nice long hem/onc hold like $CCCC or $ALLR or $IMRX
0 · Reply
Wody
Wody Jul. 2 at 3:53 PM
$ALLR buyout at $1.30?
1 · Reply
selftaught
selftaught Jul. 2 at 3:16 PM
$ALLR You are now on my list.
0 · Reply
ZacksResearch
ZacksResearch Jul. 2 at 12:26 PM
$ALLR strengthens its long-term ovarian cancer strategy with new U.S. patent protection through 2042 🔒 Allarity secured a key U.S. patent covering its stenoparib DRP companion diagnostic, reinforcing its precision medicine approach and extending intellectual property protection for its lead ovarian cancer program. The company continues advancing stenoparib in Phase 2 studies as it works toward potential FDA approval. 👉 Price target breakdown here 👇 https://www.zacks.com/stock/research/ALLR/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-38611&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_38611
1 · Reply
focafoca99
focafoca99 Jul. 1 at 12:39 PM
$ALLR awarded a key U.S. patent for its DRP companion diagnostic, expanding its biotech IP portfolio.
1 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 30 at 3:05 PM
$ALLR The Baseline Law: You can have the most miraculous clinical data in the world, but if your patent protection is weak, your corporate value is essentially zero. A biotech company's patent portfolio is completely equal in importance to its clinical trial data. They are the two pillars of a single equation: Data proves the drug works; Patents prove you can make money from it. Updated report 👇
1 · Reply
Wody
Wody Jun. 30 at 2:41 PM
$ALLR they always seem to send news in bunches…hopefully tomorrow morning!
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 30 at 1:11 PM
$ALLR 💎 🤩 👊
0 · Reply
Wody
Wody Jun. 30 at 12:47 PM
$ALLR $5 here we come…
0 · Reply
ganta7
ganta7 Jun. 30 at 12:04 PM
$ALLR press release Essential US patent Let’s see
1 · Reply
AKOkiJP
AKOkiJP Jun. 30 at 6:35 AM
0 · Reply
biotrade123
biotrade123 Jun. 29 at 7:23 PM
$ALLR apparently the proposal to dilute was passed, Google AI bottomline: The Bottom Line The shareholder meeting confirms that ALLR is a trading utility, not a long-term fundamental investment. The institutional machinery is now fully authorized to keep the company listed and alive, using retail liquidity as its primary capitalization engine. The smart strategy here is to avoid getting caught up in retail board hype during a PR pump—instead, treat the $1.15 to $1.25 zone as a high-probability accumulation bounce pocket, and ruthlessly lock in profits anywhere near $1.55 to $1.70 before the automated Tumim dilution machine can grind the momentum back down.
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 5:03 PM
$SLS sold 1K shares to buy more $ALLR $CGTX and $TNXP 🏦 💊 🧠 💤
2 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 3:56 PM
$KPTI lol Ipsen bought Kartos and not Karyopharm? How come CEO Richard Paulson and Karyopharm’s BD team couldn’t get that deal? Uncle Rolli and I could tell you why… we are focused on fixing biotechs, not just selling them on the cheap because private companies are often more poorly run than publicly traded ones. 🏦 $SLS $CCCC and $ALLR ALL DAY over the Krazy Pharm of Newton Massachusetts 😂
1 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 29 at 1:17 PM
$ALLR https://www.biospace.com/drug-development/4-ovarian-cancer-candidates-to-watch-gsk-allarity-and-more
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 27 at 5:22 AM
$ALLR $CCCC $KPTI $INCY hmm who will Incyte buy next? 💊 Vega Therapeutics will not sustain them for long … will it? 🤔
0 · Reply
Wody
Wody Jun. 26 at 7:27 PM
$ALLR how big is the drop gonna be AH and Monday?! Hope we start heading the other direction…
0 · Reply
Z_interceptor
Z_interceptor Jun. 26 at 8:44 AM
$ALLR - what a run !
1 · Reply
biotrade123
biotrade123 Jun. 25 at 5:24 PM
$ALLR all retail hoping this is the down before the pop up??
1 · Reply
BetterDayzz
BetterDayzz Jun. 25 at 8:45 AM
$ALLR It’s going to be a green summer for us. How high can it go? ✈️
0 · Reply
biotrade123
biotrade123 Jun. 24 at 1:36 PM
$ALLR could tank monday morning should the dilution vote pass??
0 · Reply